Succinimidyl ether

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: Succinimidyl ether
• 英文别名: 1-(2,5-dioxopyrrolidin-1-yl)oxypyrrolidine-2,5-dione
• 化学式: C₈H₈N₂O₅
• 分子量: 212.16
• InChiKey: SNTGWXAZMZPJPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Neuramindase Inhibitor
  申请人：Nishimura Shinichiro

  公开号：US20080113924A1

  公开（公告）日：2008-05-15

  There are provided a novel compound having irreversible inhibitory activity against neuraminidase, a therapeutic agent and a detection agent for a disease involving neuraminidase. A compound represented by the following formula (I) and a salt thereof, a production method thereof, and an application method thereof, wherein: A 1 represents an aryl group optionally having a substituent group or a heteroaryl group optionally having a substituent group; A 2 represents —CX 2 R 6 or —CHXR 6 wherein X represents —F, —Cl, —Br, or —I; R 1 represents a hydrogen atom or an alkyl group optionally having a substituent group; R 2 , R 3 , R 4 , and R 5 represent each independently —OC(═O)R 6 , —OR 6 , —N(R 6 ) 2 , —N 3 , —NHC(═NH)NHR 6 , —NHCOR 6 , —OSO 3 R 6 , —OPO 3 (R 6 ) 2 , F, Cl, Br, or I; and R 6 represents each independently a hydrogen atom, an alkyl group optionally having a substituent group, an aryl group optionally having a substituent group, or an optionally substituted heteroaryl group.

  提供了一种具有对神经氨酸酶具有不可逆抑制活性的新型化合物，一种治疗剂和一种用于涉及神经氨酸酶的疾病的检测剂。一种由以下式（I）表示的化合物及其盐，其生产方法和应用方法，其中：A1表示可选地具有取代基的芳基或可选地具有取代基的杂芳基；A2表示—CX2R6或—CHXR6，其中X表示—F、—Cl、—Br或—I；R1表示氢原子或可选地具有取代基的烷基；R2、R3、R4和R5分别独立地表示—OC(═O)R6、—OR6、—N(R6)2、—N3、—NHC(═NH)NHR6、—NHCOR6、—OSO3R6、—OPO3(R6)2、F、Cl、Br或I；和R6分别独立地表示氢原子、可选地具有取代基的烷基、可选地具有取代基的芳基或可选地取代的杂芳基。
• Substrate for immobilizing physiological material and method of fabricating same
  申请人：Samsung SDI Co., Ltd.

  公开号：EP1291655A2

  公开（公告）日：2003-03-12

  A substrate for immobilizing a physiological material is provided. The substrate comprises a substrate material; a primer layer formed on the substrate material; and an immobilization layer formed on the primer layer. The primer layer is capable of enhancing the attachment between the substrate and the immobilization layer. The substrate for immobilizing a physiological material can provide the immobilization layer with a stable, uniform, and high density through a simple process.

  提供了一种用于固定生理材料的基底。基底包括基底材料、形成于基底材料上的底层和形成于底层上的固定层。底层能够增强基底和固定层之间的附着力。这种用于固定生理物质的基底可通过简单的工艺使固定层具有稳定、均匀和高密度。
• METHOD FOR POLY SIGNAL ACTIVATION OF APOPTOSIS OF MALIGNANT SOLID TUMOUR CELLS
  申请人：Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya"

  公开号：EP3354270A1

  公开（公告）日：2018-08-01

  The invention relates to medicine and concerns a method for the poly signal activation of apoptosis of malignant solid tumour cells, carried out by means of the targeted delivery of thallium salts by surface-modified MS2 phage virions which contain a cyclic iRGD ligand that has a high affinity for the integrins avb3 and avb5 and is covalently bound with the shell and with the core, which contains genomic RNA and thallium salts. The invention provides for complex, efficient, prolonged cytotoxic action on focal and metastatic clusters of malignant solid tumour cells, while minimizing undesirable side effects on the healthy cells of an organism.

  本发明涉及医学，涉及一种多信号激活恶性实体肿瘤细胞凋亡的方法，该方法通过表面修饰的 MS2 噬菌体病毒靶向递送铊盐来实现，MS2 噬菌体病毒含有环状 iRGD 配体，该配体对整合素 avb3 和 avb5 具有高亲和力，并与外壳和内核共价结合，内核含有基因组 RNA 和铊盐。本发明可对恶性实体肿瘤细胞的病灶和转移簇产生复杂、高效、持久的细胞毒性作用，同时最大限度地减少对机体健康细胞的不良副作用。
• METHOD FOR PRODUCING HYALURONIDASE CONJUGATE WITH POLYETHYLENEPIPERAZINE DERIVATIVES AND THE USE OF THE CONJUGATE PRODUCED
  申请人：Obshchestvo S Ogranichennoy Otvetstvennostyu "NPO Petrovaks Farm"

  公开号：EP3384917A1

  公开（公告）日：2018-10-10

  This invention relates to a method for obtaining immobilized enzyme preparations, in particular to preparation and application of noval active conjugate of enzyme with a polymer carrier. Said conjugate possesses the properties of Longidaza drug and inhibits hyperplasia of connective tissue, and anti-inflammatory action, as well as it can be used for manufacturing stable, active and safe in use long-acting drugs in the form of a suppository, ointment, injection or cosmetic cream, and for making veterinary drugs. This method consists in conjugation of hyaluronidase with a water-soluble copolymer using carbodiimide or azide method. The conjugation is carried out with the use of copolymer N-oxide 1,4-ethylene piperazine, (N-carboxymethyl)-1,4-ethylene piperazine or its hydrazide, and 1,4-ethylene piperazine of general formula where n is ranging from 40 % to 90 % of total number of cells; m is ranging from 3 % to 40 % of total number of cells; n+m+1=100%,

  本发明涉及一种获得固定化酶制剂的方法，特别是酶与聚合物载体的高活性共轭物的制备和应用。所述共轭物具有 Longidaza 药物的特性，可抑制结缔组织增生，具有抗炎作用，还可用于制造稳定、活性强、使用安全的栓剂、软膏、注射剂或美容霜形式的长效药物，以及用于制造兽药。这种方法包括使用碳二亚胺法或叠氮法将透明质酸酶与水溶性共聚物共轭。这种共聚物包括 N-氧化物-1,4-乙烯哌嗪、（N-羧甲基）-1,4-乙烯哌嗪或其酰肼，以及通式为 1,4- 乙烯哌嗪的共聚物。 其中 n 占细胞总数的 40 % 至 90 %； m 占细胞总数的 3%至 40%；n+m+1=100%、
• Solution phase homogeneous assays
  申请人：Beckman Coulter, Inc.

  公开号：US10036708B2

  公开（公告）日：2018-07-31

  Methods, reagents, kits and systems are disclosed for determining an analyte in a sample suspected of containing the analyte where all reagents are soluble in aqueous solution. One assay method includes treating a sample suspected of containing the analyte under conditions such that if the analyte is present, an activator is brought into reactive configuration with a chemiluminescent compound to activates it. The sample is also treated with an agent to reduce signal not related to analyte. Finally, the sample is treated with a trigger solution thereby producing light from the activated chemiluminescent compound. No reagents are associated with a surface or other solid phase.

  本发明公开了用于测定疑似含有分析物的样品中分析物的方法、试剂、试剂盒和系统，其中所有试剂均可溶于水溶液。一种检测方法包括处理疑似含有被分析物的样品，如果样品中存在被分析物，则将活化剂与化学发光化合物反应配置，使其活化。还用一种药剂处理样品，以减少与分析物无关的信号。最后，用触发溶液处理样品，从而使活化的化学发光化合物发光。试剂与表面或其他固相无关。